{
    "name": "aducanumab",
    "comment": "Rx",
    "other_names": [
        "Aduhelm",
        "aducanumab-avwa"
    ],
    "classes": [
        "Monoclonal Antibodies",
        "Anti-amyloid Beta"
    ],
    "source": "https://reference.medscape.com/drug/aduhelm-aducanumab-4000138",
    "pregnancy": {
        "common": [
            "There are no adequate data on use in pregnant females to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "No data are available on presence of aducanumab in human milk, effects on the breastfed infants, or effects on milk production; published data from other monoclonal antibodies generally indicate low passage of monoclonal antibodies into human milk and limited systemic exposure in the breastfed infant; the effects of this limited exposure are unknown"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Angioedema and urticaria reported; promptly discontinue infusion upon first observation of any signs or symptoms consistent with a hypersensitivity reaction, and initiate appropriate therapy"
            ],
            "specific": [
                {
                    "type": "Amyloid-related imaging abnormalities (ARIA)",
                    "description": [
                        "May cause ARIA-E; observed on MRI as brain edema, sulcal effusions, and ARIA-H, which includes microhemorrhage and superficial siderosis",
                        "ARIA most commonly presents as temporary swelling in areas of the brain that usually resolves over time; other symptoms include headache, confusion, dizziness, seizures, vision changes, or nausea",
                        "Majority of ARIA observed during first 8 doses, particularly during titration; enhanced clinical vigilance recommended",
                        "Safety in patients with any pretreatment localized superficial siderosis, ≥10 brain microhemorrhages, and/or with a brain hemorrhage >1 cm within 1 year of treatment initiation has not been established",
                        "For ARIA-E or mild/moderate ARIA-H, continue treatment ",
                        "If dosing is temporarily suspended, resume at same dose and titration schedule",
                        "There are no systematic data on continued dosing following detection of radiographically moderate or severe ARIA",
                        "Refer to prescribing information for ARIA MRI classification criteria"
                    ]
                },
                {
                    "type": "Monitoring and management guidelines",
                    "description": [
                        "Recommendations for dosing in patients with ARIA-E depend on clinical symptoms and radiographic severity",
                        "Recommendations for dosing in patients with ARIA-H depend on",
                        "type of ARIA-H and radiographic severity",
                        "Use clinical judgment in considering whether to continue dosing in patients with recurrent ARIA-E",
                        "Baseline brain MRI and periodic monitoring with MRI are recommended",
                        "If patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including MRI if indicated",
                        "If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment",
                        "There is limited experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic moderate or severe ARIA-E",
                        "There are limited data on dosing patients who experienced recurrent ARIA-E",
                        "The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) is a voluntary provider-enrolled patient registry that collects information on treatments for Alzheimer’s disease, including this drug; providers may obtain information about registry at www.alz-net.orgor contact alz-net@acr.org"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Amyloid",
            "percent": "35"
        },
        {
            "name": "related imaging abnormalities",
            "percent": "21"
        },
        {
            "name": "edema",
            "percent": "19"
        },
        {
            "name": "ARIA",
            "percent": "15"
        },
        {
            "name": "E",
            "percent": "15"
        },
        {
            "name": "Headache",
            "percent": "9"
        },
        {
            "name": "ARIA",
            "percent": "8"
        },
        {
            "name": "H microhemorrhage",
            "percent": null
        },
        {
            "name": "ARIA",
            "percent": null
        },
        {
            "name": "H superficial siderosis",
            "percent": null
        },
        {
            "name": "Falls",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "delirium",
            "percent": null
        },
        {
            "name": "altered mental status",
            "percent": null
        },
        {
            "name": "disorientation",
            "percent": null
        }
    ]
}